The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding. 

Related News Articles

Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…
Headline
A study of 305 hospitalized adult COVID-19 patients in Georgia found an overrepresentation of black patients, with over a quarter lacking known risk factors,…
Blog
The AHA is committed to ensuring that all people, regardless of background or zip code, have equitable access to quality health care. As the COVID-19 pandemic…
Headline
The AHA’s Institute for Diversity and Health Equity today released a new resource highlighting steps hospitals can and are taking to address disparities that…